Anti-Cancer Drugs from Marine Sources Offer Potential Cancer Treatment

Anti-cancer drugs derived from marine sources may hold great potential in the field of cancer treatment.

The drugs are capable of targeting the microtubules and may gradually advance in the clinical setup.

Anti-cancer Drugs as a Double-Edged Sword
The key for reducing recurrence and allowing anti-cancer drugs to do work as intended has been provided by researchers.

‘Anti-cancer drugs derived from marine sources can provide new hope for cancer treatment.’

Tweet it Now

Microtubule dynamics govern crucial cellular functions and this is why microtubules are one of the most attractive anti-cancer drug targets. Microtubule targeting agents (MTAs) have the ability to treat a wide range of cancers.

However, drug induced cytotoxicity and adverse side effects have hindered their development. Another major setback is multiple drug resistance in tumor cells. These limitations have prompted the need to develop novel MTAs from alternative sources, with better therapeutic efficacies.

Recently, MTAs from marine sources have grabbed much attention due to their unique tubulin binding features and remarkable ability to reduce tumor progression.

Anti-cancer Agent May Promote Regeneration of Heart Tissue
Porcupine inhibitor is an anti-cancer agent which could promote the regeneration of heart tissue, reveals study.

The authors have summarized some of the most promising marine derived MTAs by systematically searching patent databases such as USPTO, Espacenet and WIPO for recent patents published from 2006 up to 2016.

After a critical data analysis, only those patents focusing on the chemical synthesis and/or modifications of marine derived MTAs along with a significant demonstration of their in vitro and/or in vivo activity have been reviewed.

Thailanstatin A' - a New Anti-Cancer Agent Synthesized by Rice University Lab
A novel anti-cancer agent, Thailanstatin A, which was originally isolated from a bacterial species collected in Thailand has been synthesized by scientists.

The survey of recent patents revealed that chemically modified versions of marine derived MTAs, overcoming drug resistance and their novel combination therapies increasing the overall efficacy, have positioned them as future anti-cancer blockbusters.

Of particular interest are dolastatin, laulimalide, peloruside, hemiasterlin, halichondrin, eribulin mesylate, discodermolide, dictyostatin, cryptophycin and their analogs which have significant antiproliferative potency against a wide array of cancers and are also able to overcome multidrug resistance.

New Study may Map the Path of Discovery of an Anticancer Agent
A new research has been published today that could map the path of discovery to the development of an anticancer agent

A deeper understanding of the molecular mechanisms behind the specific drug interactions and of microtubule molecular biology in general, combined with innovative therapeutic regimen would lead to major advances in the field of cancer therapy.

Source-Eurekalert